Patient leaflet - Levetiracetam Wockhardt 100 mg / ml concentrate for solution for infusion

1. What Levetiracetam concentrate for solution for infusion is and what it is used for

Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).

Levetiracetam concentrate for solution for infusion is used:

on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.
as an add-on to other antiepileptic medicines to treat:
- partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age with epilepsy
- myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy
- primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Levetiracetam concentrate for solution for infusion is an alternative for patients when administration of the antiepileptic oral levetiracetam is temporarily not feasible.

2. What you need to know before you are given Levetiracetam concentrate for solution for infusion

Do not use Levetiracetam concentrate for solution for infusion

If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before you are given Levetiracetam concentrate for solution for infusion

if you suffer from kidney problems, follow your doctor’s instructions. He/she may decide if your dose should be adjusted
if you notice any slowdown in the growth or unexpected puberty development of your child, please contact your doctor
a small number of people being treated with anti-epileptics such as levetiracetam have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor
if you have a family or medical history of irregular heart rhythm (visible on an electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.

Tell your doctor, pharmacist or nurse if any of the following side effects gets serious or last longer than a few days:

Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour
Aggravation of epilepsy
Your seizures may rarely become worse or happen more often, mainly during the first month after the start of the treatment or increase of the dose.
In a very rare form of early-onset epilepsy (epilepsy associated with SCN8A mutations) that causes multiple types of seizures and loss of skills you may notice that the seizures remain present or are becoming worse during your treatment.

If you experience any of these new symptoms while taking levetiracetam, see a doctor as soon as possible.

Children and adolescents

Levetiracetam is not indicated in children and adolescents below 16 years on its own (monotherapy).

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. You should not stop your treatment without discussing it with your doctor.

A risk of birth defects for your unborn child cannot be completely excluded.

Two studies do not suggest an increased risk of autism or intellectual disability in children born to mothers treated with levetiracetam during pregnancy. However, the available data regarding the impact of levetiracetam on neurodevelopment in children is limited.

Breast-feeding is not recommended during treatment.

Driving and using machines

Levetiracetam may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.

Levetiracetam concentrate for solution for infusion contains sodium

For 250mg & 500mg dose:

This medicine contains less than 1mmol sodium (23mg) per vial, that is to say essentially 'sodium-free'.

1000mg dose/10ml (two 5ml vials):

This medicine contains 38mg sodium per 10ml, equivalent to 1.9% of the WHO recommended maximum daily intake of 2g sodium for an adult.

1500mg dose/15ml (three 5ml vials):

This medicine contains 57mg sodium per 15ml, equivalent to 2.85% of the WHO recommended maximum daily intake of 2g sodium for an adult.

3. How Levetiracetam concentrate for solution for infusion is given

A doctor or a nurse will administer your levetiracetam as an intravenous infusion.

Levetiracetam must be administered twice a day, once in the morning and once in the evening, at about the same time each day.

The intravenous formulation is an alternative to your oral administration. You can switch from the film-coated tablets or from the oral solution to the intravenous formulation or reverse directly without dose adaptation. Your total daily dose and frequency of administration remain identical.

Adjunctive therapy and Monotherapy (from 16 years of age).

Adults (≥18 years) and adolescents (12 to 17 years) weighing 50kg or more:

Recommended dose: between 1000mg and 3000mg each day.

When you will first start treatment with levetiracetam, your doctor will prescribe you a lower dose during 2 weeks before giving you the lowest daily dose.

Dose in children (4 to 11 years) and adolescents (12 to 17 years) weighing less than 50kg:

Recommended dose: between 20mg per kg bodyweight and 60mg per kg bodyweight each day.

Method and route of administration:

Levetiracetam concentrate for solution for infusion is for intravenous use.

The recommended dose must be diluted in at least 100ml of a compatible diluent and infused over 15 minutes.

For doctors and nurses, more detailed direction for the proper use of levetiracetam is provided in Section 6.

Duration of treatment:

There is no experience with administration of intravenous levetiracetam for a longer period than 4 days.

If you stop using Levetiracetam:

If stopping treatment, as with other antiepileptic medicines, levetiracetam should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your treatment with levetiracetam, he/she will instruct you about the gradual withdrawal of levetiracetam.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately, or go to your nearest emergency department, if you experience:

weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction
swelling of the face, lips, tongue and throat (Quincke’s oedema)
flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) enlarged lymph nodes and the involvement of other body organs (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])
symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function
a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)
a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)
signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.

The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.

Very common: may affect more than 1 in 10 people

nasopharyngitis
somnolence (sleepiness), headache.

Common: may affect up to 1 in 10 people

anorexia (loss of appetite)
depression, hostility or aggression, anxiety, insomnia, nervousness or irritability
convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling)
vertigo (sensation of rotation)
cough
abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea
rash
asthenia/fatigue (tiredness).

Uncommon: may affect up to 1 in 100 people

decreased number of blood platelets, decreased number of white blood cells
weight decrease, weight increase
suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation
amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration)
diplopia (double vision), blurred vision
elevated/abnormal values in a liver function test
hair loss, eczema, pruritis
muscle weakness myalgia (muscle pain)
injury.

Rare: may affect up to 1 in 1,000 people

infection
decreased number of all blood cell types
severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], quincke’s oedema [swelling of the face, lips, tongue and throat])
decreased blood sodium concentration
suicide, personality disorders (behavioural problems), thinking abnormally (slow thinking, unable to concentrate)
delirium
encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms)
seizures may become worse or happen more often
uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity)
change of the heart rhythm (Electrocardiogram)
pancreatitis
liver failure, hepatitis
sudden decrease in kidney function
skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)
rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.
limp or difficulty walking.

Evidence also suggests a possible predisposition of the Japanese population to neuroleptic malignant syndrome (NMS).

Very rare: may affect up to 1 in 10,000 people

repeated unwanted thoughts or sensations or the urge to do something over and over again (Obsessive Compulsive Disorder).

Reporting of side effects

If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme

Website: http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple

App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Levetiracetam concentrate for solution for infusion

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the vial and carton box after EXP.

The expiry date refers to the last day of the month.

Store below 25°C. Chemical and physical in-use stability has been demonstrated for 7 days at 5°C to 22°C when diluted with 9mg/ml (0.9%) sodium chloride, 5% dextrose or Hartmann’s Solution to 2mg/ml. From a microbiological point of view, in-use storage time and conditions prior to use are the responsibility of the user.

Do not use if the product shows signs of deterioration such as discolouration.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

The active substance is levetiracetam. Each ml of solution for infusion contains 100mg of levetiracetam.
The other ingredients are sodium chloride, sodium acetate trihydrate, acetic acid solution and water for injections.

Levetiracetam Wockhardt 100mg/ml concentrate for solution for infusion is a clear, colourless, liquid. It is packed in a cardboard box containing five or ten vials.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing authorisation holder: Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, UK.

Manufacturer: CP Pharmaceuticals Ltd, Ash Road North, Wrexham, LL13 9UF, UK.

Other formats:

To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:

0800 198 5000 (UK only)

Please be ready to give the following information:

Product name	Reference number
Levetiracetam Wockhardt 100mg/ml concentrate for solution or infusion	29831/0526

This is a service provided by the Royal National Institute of Blind People.

This leaflet was last revised in 02/2026

The following information is intended for healthcare professionals only:

Directions for the proper use of Levetiracetam 100mg/ml concentrate for solution for infusion is provided in Section 3.

One vial of Levetiracetam 100mg/ml concentrate for solution for infusion contains 500mg of levetiracetam (5ml concentrate of 100mg/ml). See Table 1 for the recommended preparation and administration of Levetiracetam 100mg/ml concentrate for solution for infusion to achieve a total daily dose of 500mg, 1000mg, 2000mg or 3000mg in two divided doses.

Table 1. Preparation and administration of Levetiracetam 100mg/ml concentrate for solution for infusion

Dose	Withdrawal volume	Volume of diluent	Infusion Time	Frequency of Administration	Total Daily Dose
250mg	2.5ml (half 5ml vial)	100ml	15 minutes	Twice Daily	500mg/day
500mg	5ml (one 5ml vial)	100ml	15 minutes	Twice Daily	1000mg/day
1000mg	10ml (two 5ml vials)	100ml	15 minutes	Twice Daily	2000mg/day
1500mg	15ml (three 5ml vials)	100ml	15 minutes	Twice Daily	3000mg/day

This medicinal product is for single use only; any unused solution should be discarded.